News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Actelion Ltd. Swings to Profit, Key Drug Tracleer Disappoints
April 22, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, April 22 (Reuters) - Swiss biotech company Actelion Ltd swung to a first-quarter net profit of 48 million Swiss francs ($47.43 million), but results were hit by the weak dollar and sales of key drug Tracleer disappointed.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Executive appointments
Merck Reorganizes Human Health Work Into Two New Units
February 23, 2026
·
1 min read
·
Annalee Armstrong
Weight loss
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
February 23, 2026
·
4 min read
·
Annalee Armstrong
Layoff Tracker
BMS, Catalent Further Whittle Workforces
February 23, 2026
·
57 min read
·
BioSpace Editorial Staff
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
February 19, 2026
·
1 min read
·
Jennifer Smith-Parker
